Host cell targets in HCV therapy: Novel strategy or proven practice?

Antiviral Chemistry and Chemotherapy

Volumn 16, Issue 2, 2005, Pages 69-90

  Klebl, Bert M ^a   Kurtenbach, Alexander ^a   Salassidis, Kostas ^a   Daub, Henrik ^a   Herget, Thomas ^b  

^a Axxima Pharmaceuticals AG   (Germany)

^b MERCK KGAA   (Germany)

Author keywords

(in)direct antiviral agent compound; Glutathione peroxidase; HCV; Indirect (cellular) and direct (viral) antiviral targets; Interferon; Protein kinase; Ribavirin; Signal transduction

Indexed keywords

3 [2 [(2 TERT BUTYLPHENYLAMINOOXALYL)AMINO]PROPIONYLAMINO] 4 OXO 5 (2,3,5,6 TETRAFLUOROPHENOXY)PENTANOIC ACID; ALANINE AMINOTRANSFERASE; ALBUMIN ALPHA INTERFERON; ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALPHAN1 INTERFERON; ALPHAN3 INTERFERON; AMANTADINE; ANA 971; ANTIFIBROTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; BETA INTERFERON; BETA1A INTERFERON; CILUPREVIR; CIVACIR; CONSENSUS INTERFERON; COPESUS; CPG 10101; FURAPROFEN; GAMMA1B INTERFERON; GENITICIN; HCV 086; HCVIMF 59; HEPATITIS C VACCINE; HEPEX; HISTAMINE; IMIQUIMOD; IMMUNOMODULATING AGENT; INTERCELL; INTERFERON; IP 501; ISATORIBINE; JTK 003; JTK 109; KPE 02003002; MERIMEPODIB; MULTIFERON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMEGA INTERFERON; PEG ALPHACON; PEG INTRON A; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; R 1479; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RESIQUIMOD; RIBAMIDINE; RIBAVIRIN; RITUXAM; RITUXIMAB; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; UNINDEXED DRUG; UT 231 B; VALOPICITABINE; VIRUS RNA; VX 950; NEW DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE DISEASE; BLOOD TRANSFUSION; BONE MARROW TOXICITY; CELL CULTURE; CHIMPANZEE; CLINICAL TRIAL; CRYOGLOBULINEMIA; DISEASE TRANSMISSION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; GENOTYPE; GLOMERULONEPHRITIS; GLUCOSE INTOLERANCE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST CELL; HUMAN; INCIDENCE; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER BIOPSY; LIVER CARCINOMA; LIVER CIRRHOSIS; METABOLIC BONE DISEASE; NEUTROPENIA; NONHUMAN; PATHOGENESIS; PATHOGENICITY; PRIORITY JOURNAL; REPLICON; REVIEW; RNA REPLICATION; SIDE EFFECT; TISSUE CULTURE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DELIVERY SYSTEM; IMMUNOLOGY; PHYSIOLOGY;

ANIMALS; ANTIVIRAL AGENTS; DRUG DELIVERY SYSTEMS; DRUGS, INVESTIGATIONAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MOLECULAR STRUCTURE;

EID: 17144396869     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020501600201     Document Type: Review

References (134)

1. Aoki H, Hayashi J, Moriyama M, Arakawa Y & Hino O (2000) Hepatitis C virus core protein interacts with 14-3-3 protein and activates the kinase Raf-1. Journal of Virology 74:1736-1741.
2. Arima N, Kao CY, Licht T, Padmanabhan R, Sasaguri Y & Padmanabhan R (2001) Modulation of cell growth by the hepatitis C virus nonstructural protein NS5A. Journal of Biological Chemistry 276:12675-12684.
3. Bartenschlager R & Lohmann V (2000) Replication of hepatitis C virus. Journal of General Virology 81:1631-1648.
4. Bartenschlager R & Lohmann V (2001) Novel cell culture systems for the hepatitis C virus. Antiviral Research 52:1-17.
5. Bartenschlager R (2002) Hepatitis C virus replicons: potential role for drug development. Nature Reviews Drug Discovery 1:911-916.
6. Bigger CB, Brasky KM & Lanford RE (2001) DNA microarrays analysis of chimpanzee liver during acute resolving hepatitis C virus infection. Journal of Virology 75:7059-7066.
7. Billich A (2002) Thymosin α1. Current Opinion in Investigational Drugs 3:698-707.
8. Blight KJ, Kolykhalov AA & Rice CM (2000) Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974.
9. Boehme KW & Compton T (2004) Innate sensing of viruses by toll-like receptors. Journal of Virology 78:7867-7873.
10. Bngelius-Flohé R (1999) Tissue-specific function of individual glutathione peroxidases. Free Radical Biology & Medicine 27:951-965.
11. Brigelius-Flohé R & Flohé L (2003) Is there a role of glutathione peroxidase in signaling and differentiation? Biofactors 17:93-102.
12. Bukh J, Pietschmann T, Lohmann V, Krieger N, Faulk K, Engle RE, Govindarajan S, Shapiro M, St Claire M & Bartenschlager R (2002) Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proceedings of the National Academy of Sciences, USA 99:14416-14421.
13. Carithers RL Jr & Emerson SS (1997) Therapy of hepatitis C: metaanalysis of Interferon alfa-2b trials. Hepatology 26(Suppl 1):83S-88S.
14. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW & Houghton M (1989) Isolation of a cDNA clone from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362.
15. Cohen P (1999) The development and therapeutic potential of protein kinase inhibitors. Current Opinion in Chemical Biology 3:459-465.
16. Cohen P (2000) The regulation of protein function by multisite phosphorylation - a 25 year update. Trends in Biochemical Sciences 25:596-601.
17. Coito C, Diamond DL, Neddermann P, Korth MJ & Katze MG (2004) High-throughput screening of the yeast kinome: identification of human serine/threonine protein kinases that phosphorylate the hepatitis C virus NS5A protein. Journal of Virology 78:3502-3513.
18. Craxi A, Ideo G, Demelia L, Picciotto A, Alberti A, Pitaro M & Rizzetto M (2003) Open, multicenter, randomized, controlled trial to compare safety and efficacy of r-hIFN beta 1a alone or in combination with ribavirin in HCV naïve patients. Digestive Diseases & Sciences 35(Suppl 1):A14.
19. Dagan S & Eren R (2003) Therapeutic antibodies against viral hepatitis. Current Opinion in Molecular Therapeutics 5:148-155.
20. Dammacco F, Sansonno D, Piccoli C, Racanelli V, D'Amore FP & Lauletta G (2000) The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and overt B-cell malignancy. Seminars in Liver Disease 20:143-157.
21. Darnell JE Jr, Kerr IM & Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421.
22. Daub H, Godl K, Brehmer D, Klebl B & Müller G (2004) Evaluation of kinase inhibitor selectivity by chemical proteomics. Assay & Drug Development Technologies 2:215-224.
23. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling M-H & Albrecht JK (1998) Interferon-alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. New England Journal of Medicine 339:1493-1499.
24. De Clercq E (2002) Strategies in the design of antiviral drugs. Nature Reviews Drug Discovery 1:13-24.
25. De Clercq E (2004) Antiviral drugs in current clinical use. Journal of Clinical Virology 30:115-133.
26. DeFilippis V, Raggo C, Moses A & Früh K (2003) Functional genomics in virology and antiviral drug discovery. Trends in Biotechnology 21:452-457.
27. De Ledinghen V, Trimoulet P, Winnock M, Foucher J, Bourliere M, Desmorat H, Canva V, Capron D, Levy S, Mion F, Mannant PR, Chene G, Fleury H, Couzigou P & Bernard PH; French Multicenter Study Group (2002) Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C. Hepatology 36:672-680.
28. Di Bisceglie AM, Shindo M, Fong T-L, Fried MW, Swain MG, Bergasa NV, Axiotis CA, Waggoner JG, Park Y & Hoofnagle JH (1992) A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 16:649-654.
29. Dockrell DH &, Kinghorn GR (2001) Imiquimod and resiquimod as novel immunomodulators. Journal of Antimicrobial Chemotherapy 48:751-755.
30. Doly J, Civas A, Navarro S & Uze G (1998) Type I interferons: expression and signalization. Cellular & Molecular Life Science 54:1109-1121.
31. Durantel D, Escuret V & Zoulim F (2003) Current and emerging therapeutic approaches to hepatitis C infection. Expert Review of Anti-infective Therapy 1:441-454.
32. Dymock BW, Jones PS & Wilson FX (2000) Novel approaches to the treatment of hepatitis C virus infection. Antiviral Chemistry & Chemotherapy 11:79-96.
33. Engh RA & Bossemeyer D (2001) The protein kinase activity modulation sites: mechanisms for cellular regulation - targets for therapeutic intervention. Advances in Enzyme Regulation 41:121-149.
34. Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, Mushahwar IK, Desai SM, Miller RH, Ogata N & Purcell RH (1992) Lack of protective immunity against reinfection with hepatitis C virus. Science 258:135-140.
35. Fattovich G, Zagni I, Minola E, Felder M, Rovere P, Carlotto A, Suppressa S, Miracolo A, Paternoster C, Rizzo C, Rossini A, Benedetti P, Capanni M, Ferrara C, Costa P, Bertin T, Pantalena M, Lomonaco L, Scattolini C, Mazzella G, Giusti M, Boccia S, Milani S, Marin R, Lisa Ribero M & Tagger A (2003) A randomized trial of consensus interferon in combination with ribavirin as initial treatment for chronic hepatitis C. Journal of Hepatology 39:843-849.
36. Festi D, Sandri L, Mazzella G, Roda E, Sacco T, Staniscia T, Capodicasa S, Vestito A & Colecchia A (2004) Safety of interferon β treatment for chronic HCV patients. World Journal of Gastroenterology 10:12-16.
37. Forton DM, Karayiannis P, Mahmud N, Taylor-Robinson SD, Thomas HC (2004) Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. Journal of Virology 78:5170-5183.
38. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J & Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine 347:975-982.
39. Fruh K, Simmen K, Luukkonen BG, Bell YC & Ghazal P (2001) Virogenomics: a novel approach to antiviral drug discovery. Drug Discovery Today 6:621-627.
40. Furusyo N, Hayashi J, Ohmiya M, Sawayama Y, Kawakami Y, Ariyama I, Kinukawa N & Kashiwagi S (1999) Differences between interferon-α and -β treatment for patients with chronic hepatitis C virus infection. Digestive Diseases & Sciences 44:608-617.
41. Galun E, Burakova T, Ketzinel M, Lubin I, Shezen E, Kahana Y, Eid A, Ilan Y, Rivkind A, Pizov G, Shouval D & Reisner Y (1995) Hepatitis C virus viremia in SCID→BNX mouse chimera. Journal of Infectious Diseases 172:25-30.
42. Godl K, Wissing J, Kurtenbach A, Habenberger P, Blencke S, Gutbrod H, Salassidis K, Stein-Gerlach M, Missio A, Cotten M & Daub H (2003) An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proceedings of the National Academy of Sciences, USA 100:15434-15439.
43. Gong G, Waris G, Tanveer R & Siddiqui A (2001) Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-κB. Proceedings of the National Academy of Sciences, USA 98:9599-9604.
44. Goodbourn S, Didcock L & Randall RE (2000) Interferons: cell signalling, immune modulation, antiviral responses and virus counter-measures. Journal of General Virology 81:2341-2364.
45. Ghosh AK, Steele R, Meyer K, Ray R & Ray RB (1999) Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. Journal of General Virology 80:1179-1183.
46. He Y, Tan SL, Tareen SU, Vijaysri S, Langland JO, Jacobs BL & Katze MG (2001) Regulation of mRNA translation and cellular signaling by hepatitis C virus nonstructural protein NS5A. Journal of Virology 75:5090-5098.
47. He Y, Nakao H, Tan SL, Polyak SJ, Neddermann P, Vijaysri S, Jacobs BL & Katze MG (2002) Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase. Journal of Virology 76:9207-9217.
48. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, & Akira S (2002) Small antiviral compound activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature Immunology 3:196-200.
49. Heim MH, Moradpour D & Blum HE (1999) Expression of hepatitis C virus protein inhibits signal transduction through the Jak-STAT pathway. Journal of Virology 73:8469-8475.
50. Heim MH (2000) Intracellular signalling and antiviral effects of interferons. Digestive & Liver Disease 32:257-263.
51. Hoglen NC, Chen L-S, Fisher CD, Hirakawa BP, Groessl T & Contreras PC (2003) Characterization of IDN-6556 (3-{2-(2-tert-butyl-phenylaminooxalyl)- amino]-priopionylamino}-4-oxo-5-(2,3,5,6-tetrafluoro-phcnoxy)-pentanoic acid): a liver-targeted caspase inhibitor. Journal of Pharmacology & Experimental Therapeutics 309:634-640.
52. Hopkins AL & Groom CR (2002) The druggable genome. Nature Re-view Drug Discovery 1:727-730.
53. Hugle T & Cerny A (2003) Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C. Reviews in Medical Virology 13:361-371.
54. Hwang SB, Park KJ, Ki YS, Sung YC & Lai MM (1997) Hepatitis C virus NS5B protein is a membrane-associated phosphoprotein with a predominantly perinuclear localization. Journal of Virology 227:439-446.
55. Ichimura H & Levy JA (1995) Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus. Journal of Virology 211:554-560.
56. Ide Y, Tanimoto A, Sasaguri Y & Padmanabhan R (1997) Hepatitis C virus NS5A protein is phosphorylated in vitro by a stably bound protein kinase from HeLa cells and by cAMP-dependent protein kinase A-alpha catalytic subunit. Gene 201:151-158.
57. Ikeda F, Shimomura H, Miyake M, Fujioka, S-I, Itoh M, Takahashi A, Iwasaki, Y, Sakaguchi K, Yamamoto K, Higashi T & Tsuji T (2000) Early clearance of circulating hepatitis C virus enhanced by induction therapy with twice-a-day intravenous infection of IFN-β. Journal of Interferon Cytokine Research 20:831-836.
58. Ilan E, Arazi J, Nussbaum O, Zauberman A, Eren R, Lubin I, Neville L, Ben-Moshe O, Kischitzky A, Litchi A, Margalit I, Gopher J, Mounir S, Cai W, Daudi N, Eid A, Jurim O, Czerniak A, Galun E & Dagan S (2002) The hepatitis C virus (HCV)-Trimera mouse: a model for evaluation of agents against HCV. Journal of Infectious Diseases 185:153-161.
59. Isaacs A & Lindenmann J (1957) Virus interference. I. The interferon. Proceedings of the Royal Society of London. Series B: Biological Sciences 147:258-267.
60. Kakizaki S, Takagi H, Yamada T, Ichikawa T, Abe T, Sohara N, Kosone T, Kaneko M, Takezawa J, Takayama H, Nagamine T & Mori M (1999) Evaluation of twice-daily administration of interferon-β for chronic hepatitis C. Journal of Viral Hepatitis 6:315-319.
61. Katze MG, Kwieciszewski B, Goodlett DR, Blakely CM, Neddermann P, Tan S-L & Aebersold R (2000) Ser2194 is a highly conserved major phosphorylation site of the hepatitis C virus nonstructural protein NS5A. Journal of Virology 278:501-513.
62. Katze MG, He Y & Gale M Jr (2002) Viruses and interferon: a fight for supremacy. Nature Reviews Immunology 2:675-687.
63. Kim J, Lee D & Choe J (1999) Hepatitis C virus NS5A protein is phosphorylated by casein kinase II. Biochemical & Biophysical Research Communications 257:777-781.
64. Kim WR (2002) The burden of hepatitis C in the United States. Hepatology 36:S30-S34.
65. Kim S-J, Kim J-H, Kim Y-G, Lim H-S & Oh J-W (2004) Protein kinase C-related kinase 2 regulates hepatitis C virus RNA polymerase function by phosphorylation. Journal of Biological Chemistry 279:50031-50041.
66. Klebl BM (2004) Stacking up the armoury against viruses. Drug Discovery Today 9:162-164.
67. Klebl BM, Daub H & Keri G (2004) Chemical kinomics. In Chemogenomics in Drug Discovery, vol. 22; pp.167-190. Edited by H Kubinyi and G Müller. Weinheim: Wiley-VCH.
68. Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM & Rice CM (1997) Transmission of hepatitis C by intraheptic inoculation with transcribed RNA. Science 277:570-574.
69. Koch JO & Bartenschlager R (1999) Modulation of hepatitis C virus NS5A hyperphosphorylation by nonstructural proteins NS3, NS4A, and NS4B. Journal of Virology 73:7138-7146.
70. Krieger N, Lohmann V & Bartenschlager R (2001) Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. Journal of Virology 75:4614-4624.
71. Lamarre D, Anderson PC, Bailey M, Beauheu P, Bolger G, Bonneau P, Bös M, Cameron DR, Cartier M, Cordingley MG, Faucher A-M, Goudreau N, Kawai SH, Kukolj G, Lagace L, LaPlante SR, Narjes J, Poupart M-A, Rancourt J, Sentjens, RE, St George R, Simoneau B, Steinmann G, Thibeault D, Tsantrizos YS, Weldon SM, Yong C-L & Llinàs-Brunet M (2003) An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186-189.
72. Lanford RE, Chavez D, Guerra B, Lau JY, Hong Z, Brasky KM & Beames B (2001) Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. Journal of Virology 75:8074-8081.
73. Lear JD (2003) Proton conduction through the M2 protein of the influenza A virus; a quantitative, mechanistic analysis of experimental data. FEBS Letters 552:17-22.
74. Lee H, Hanes J & Johnson KA (2003) Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 42:14711-14719.
75. Levy JA (2003) The search for the CD8+ cell anti-HIV factor (CAF). Trends in Immunology 24:628-632.
76. Levy JA, Scott I & Mackewicz C (2003) Protection from HIV/AIDS: the importance of innate immunity. Clinical Immunology 108:167-174.
77. Lohmann V, Korner F, Koch J, Herian U, Theilmann L & Bartenschlager R (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
78. Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J & Gallo RC (1994) Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 226:801-805.
79. Lu W & Ou JH (2002) Phosphorylation of hepatitis C virus core protein by protein kinase A and protein kinase C. Journal of Virology 300:20-30.
80. Macdonald A, Crowder K, Street A, McCormick C, Saksela K & Harris M (2003) The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing ras-ERK pathway signaling. Journal of Biological Chemistry 278:17775-17784.
81. Macdonald A, Crowder K, Street A, McCormick C & Harris M (2004) The hepatitis C virus NS5A protein binds to members of the Src family of tyrosine kinases and regulates kinase activity. Journal of General Virology 85:721-729.
82. Magnet MK, Bonelli RM & Kapfhammer HP (2004) Amantadine in the akinetic-rigid variant of Huntington's disease. Annals of Pharmacotherapy 38:1194-1196.
83. Majumder M, Ghosh AK, Steele R, Ray R & Ray RB (2001) Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. Journal of Virology 75:1401-1407.
84. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M & Albrecht JK (1998) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358:958-965.
85. Marcellin P & Boyer N (2003) Chronical viral hepatitis. Best Practice & Research Clinical Gastroenterology 17:259-275.
86. McHutchinson JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling M-H, Cort S & Albrecht JK (1998) Interferon-alpha-2h alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England Journal of Medicine 339:1485-1492.
87. Mehta AS, Gu B, Conyers B, Ouzounov S, Wang L, Moriarty RM, Dwek RA & Block TM (2004) α-Galactosylceramide and novel synthetic glycolipids directly induce the innate host defense pathway and have direct activity against hepatitis B and C viruses. Antimicrobial Agents & Chemotherapy 48:2085-2090.
88. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, Addison WR, Fischer KP, Churchill TA, Lakey JR, Tyrrell DL & Kneteman NM (2001) Hepatitis C virus replication in mice with chimeric human livers. Nature Medicine 7:927-933.
89. Monier RL & Wilcox R (2004) Metabolic complications associated with the use of highly active antiretroviral therapy in HIV-1-infected adults. American Journal of the Medical Sciences 328:48-56.
90. Morbitzer M & Herget T (2005) Expression of gastrointestinal glutathione peroxidase is inversely correlated to the presence of hepatitis C virus subgenomic RNA in human liver cells. Journal of Biological Chemistry 280:8831-8841.
91. Müller G (2003) Medicinal chemistry of target family-directed masterkeys. Drug Discovery Today 8:681-691.
92. Nomura H, Sou S, Nagahama T, Hayashi J, Kashiwagi S & Ishibashi H (2004) Efficacy of early retreatment with interferon β for relapse in patients with genotype Ib chronic hepatitis C. Hepatology Research 28:36-40.
93. Park KJ, Choi SH, Choi DH, Park JM, Yie SW, Lee SY & Hwang SB (2003) Hepatitis C virus NS5A protein modulates c-Jun N-terminal kinase through interaction with tumour necrosis factor receptor-associated factor 2. Journal of Biological Chemistry 278:30711-30718.
94. Pause A, Kukolj G, Bailey M, Brault M, Do F, Halmos T, Lagacé L, Maurice R, Marquis M, McKercher G, Pellerin C, Pilote L, Thibeault D & Lamarre D (2003) An NS3 serine protcasc inhibitor abrogates replication of subgenomic hepatitis C virus RNA. Journal of Biological Chemistry 278:20374-20380.
95. Patterson JL & Fernandez-Larsson (1990) Molecular mechanism of action of ribavirin. Reviews of Infectious Diseases 12:1139-1146.
96. Pavlovic D, Neville DCA, Argaud O, Blumberg B, Dwek RA, Fischer WB & Zitzmann N (2003) The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proceedings of the National Academy of Sciences, USA 100:6104-6108.
97. Pawlotsky J-M & McHutchison JG (2004) Hepatitis C. Development of new drugs and clinical trials: promises and pitfalls. Hepatology 39:554-567.
98. Pham TN, MacParland SA, Mulrooney PM, Cooksley H, Naoumov NV & Michalak TI (2004) Hepatitis C virus persistence after spontaneous or treatment-induced resolution of hepatitis C. Journal of Virology 78:5867-5874.
99. Pellicano R, Palmas F, Cariti G, Tappero G, Boero M, Tabone M, Suriani R, Pontisso P, Pitaro M & Rizzetto M (2002) Re-treatment with interferon-beta of patients with chronic hepatitis C virus infection. European Journal of Gastroenterology & Hepatology 14:1377-1382.
100. Pepinsky RB, Lepage DJ, Gill A, Chakraborty A, Vaidyanathan S, Green M, Baker DP, Whalley E, Hochman PS & Martin P (2001) Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-β-1a with preserved in vitro bioactivity. Journal of Pharmacology & Experimental Therapeutics 297:1059-1066.
101. Pflugheher J, Fredericksen B, Sumpter R Jr, Wang C, Ware F, Sodora DL & Gale M Jr (2002) Regulation of PKR and IRF-1 during hepatitis C virus RNA replication. Proceedings of the National Academy of Sciences, USA 99:4650-4655.
102. Pietschmann, T, Lohmann V, Rutter G, Kurpanek K & Bartenschlager R (2001) Characterization of cell lines carrying self-replicating hepatitis C virus RNAs. Journal of Virology 75:1252-1264.
103. Pietschmann T & Bartenschlager R (2003) Tissue culture and animal models for hepatitis C virus. Clinics in Liver Disease 7:23-43.
104. Potter SJ, Chew CB, Steain M, Dwyer DE & Saksena NK (2004) Obstacles to successful antiretroviral treatment of HIV-1 infection: problems & perspectives. Indian Journal of Medical Research 119:217-237.
105. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C & Albrecht J (1998) Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352:1426-1432.
106. Poynard T, Yuen M-F, Ratziu V & Lai CL (2003) Viral hepatitis C. Lancet 362:2095-2100.
107. Reed KE, Xu J & Rice CM (1997) Phosphorylation of the hepatitis C virus NS5A protein in vitro and in vivo: properties of the NS5A-associated kinase. Journal of Virology 71:7187-7197.
108. Rehermann B & Chisari FV (2000) Cell mediated immune response to the hepatitis C virus. Current Topics in Microbiology & Immunology 242:299-325.
109. Reusser P, Einsele H, Lee J, Volin L, Rovira M, Engelhard D, Finke J, Cordonnier C, Link H & Ljungman P for the infectious Disease Working Party of the European Group for Blood and Marrow Transplantation (2002) Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood 99:1159-1164.
110. Rumi M, Del Ninno E, Parravicini ML, Romeo R, Soffredini R, Donato MF, Wilber J, Russo A & Colombo M (1996) A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C. Hepatology 24:1366-1370.
111. Sarcar B, Ghosh AK, Steele R, Ray R & Ray RB (2004) Hepatitis C virus NS5A mediated STAT3 activation requires co-operation of Jak1 kinase. Journal of Virology 322:51-60.
112. Schang LM (2004) Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication. Biochimica et Biophysica ACTA/General Subjects 1697:197-209.
113. Senturk H, Ersoz G, Ozaras R, Kaymakoglu S, Bozkaya H, Akdogan M, Mert A, Bozdayi M, Tabak F, Venice N & Ozbay G (2003) Interferon-alpha2b induction treatment with or without ribavirin in chronic hepatitis C: a multicentcr, randomized, controlled trial. Digestive Diseases & Sciences 48:1124-1129.
114. Shimizu YK, Weiner AJ, Rosenblatt J, Wong DC, Shapiro M, Popkin T, Houghton M, Alter HJ & Purcell RH (1990) Early-events in hepatitis C virus infection of chimpanzees. Proceedings of the National Academy of Sciences, USA 87:6441-6444.
115. Shiratori Y, Perelson AS, Weinberger L, Imazeki F, Yokosuka O, Nakata R, Ihori M, Hirota K, Ono N, Kuroda H, Motojima T, Nishigaki M & Omata M (2000) Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta. Journal of Hepatology 33:313-322.
116. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT & Robins RK (1972) Broad spectrum antiviral activity of Virazole: 1-β-D-ribofuranosyl- 1,2,4-triazole-3-carboxamide. Science 177:705-706.
117. Street A, Macdonald A, Crowder K & Harris M (2004) The hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade. Journal of Biological Chemistry 279:12232-12241.
118. Stuyver LJ, McBrayer TR, Tharnish PM, Hassan AE, Chu CK, Pankiewicz KW, Watanabe KA, Schinazi RF & Otto MJ (2003) Dynamics of subgenomic hepatitis C virus replicon RNA levels in Huh-7 cells after exposure to nucleoside antimetabolites. Journal of Virology 77:10689-10694.
119. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, Wieland S, Bukh J, Purcell RH, Schultz, PG & Chisari FV (2002) Genomic analysis of the host response to hepatitis C virus infection. Proceedings of the National Academy of Sciences, USA 99:15669-15674.
120. Tam RC, Lau JYN & Hong Z (2002) Mechanisms of action of ribavirin in antiviral therapies. Antiviral Chemistry & Chemotherapy 12:261-272.
121. Tan, SL, Nakao H, He Y, Vijaysri S, Neddermann P, Jacobs BL, Mayer BJ & Katze MG (1999) NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proceedings of the National Academy of Sciences, USA 96:5533-5538.
122. Tan S-L & Katze MC (2001) How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. Journal of Virology 284:1-12.
123. Tan S-L, Pause A, Shi Y & Sonenberg N (2002) Hepatitis C therapeutics: current status and emerging strategies. Nature Review Drug Discovery 1:867-881.
124. Tang H, Peng T & Wong-Staal F (2002) Novel technologies for studying virus-host interaction and discovering new drug targets for HCV and HIV. Current Opinion in Pharmacology 2:541-547.
125. Tanji Y, Kaneko T, Satoh S & Shimotohno K (1995) Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. Journal of Virology 69:3980-3986.
126. Thimme R, Bukh J, Spangenberg HC, Wieland S, Pemberton J, Steiger C, Govindarajan S, Purcell RH & Chisari FV (2002) Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proceedings of the National Academy of Sciences, USA 99:15661-15668.
127. Valentino KL, Gutierrez M, Sanchez R, Winship MJ & Shapiro DA (2003) First clinical trial of a novel caspase inhibitor, IDN-6556, improves liver enzymes. International Journal of Clinical Pharmacology 41:441-449.
128. 2a (40kDa)/ribavirin combination for the treatment of chronic hepatitis C infection. Expert Review of Anti-infective Therapy 1:423-431.
129. Vollmer J, Rankin R, Hartmann H, Jurk M, Samulowitz U, Wader T, Janosch A, Schetter C & Krieg AM (2004) Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. Antimicrobial Agents & Chemotherapy 48:2314-2317.
130. Waris G, Livolsi A, Imbert V, Peyron JF & Siddiqui A (2003) Hepatitis C virus NS5A and subgenomic replicon activate NF-κB via tyrosine phosphorylation of IκBα and its degradation by cal-pain protease. Journal of Biological Chemistry 278:40778-40787.
131. Wright T, Shiffman ML, Knox S, Ette E, Kauffman RS & Alam J (1999) Dose range-finding study of VX-497, a oral IMPDH inhibitor, in patients with hepatitis C. Hepatology 30:408A.
132. Wu JJ, Huang DB & Tyring SK (2004) Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. Antiviral Research 64:79-83.
133. Zech B, Kurtenbach A, Krieger N, Strand D, Blencke S, Morbitzer M, Salassidis K, Cotten M, Wissing J, Obert S, Bartenschlager R, Herget T & Daub H (2003) Identification and characterization of amphiphysin II as a novel cellular interaction partner of the hepatitis C virus NS5A protein. Journal of General Virology 84:555-560.
134. Zoulim F, Chevallier M, Maynard M & Trepo C (2003) Clinical consequences of hepatitis C virus infection. Reviews in Medical Virology 13:57-68.